 |
|
Effect of Denosumab on the Change of Osteoclast Precursors Compared to Zoledronate Treatment in Postmenopausal Women with Osteoporosis
Sung Hye Kong, Jung Hee Kim, Sang Wan Kim, Ae Jin Jeong, Song-Hee Lee, Sang-Kyu Ye, Chan Soo Shin
J Bone Metab. 2022;29(2):93-101. Published online 2022 May 31 DOI: https://doi.org/10.11005/jbm.2022.29.2.93
|
|
Citations to this article as recorded by
 Positive und negative (Neben)Effekte bei
Osteoporose-Sequenztherapie
Barbara Obermayer-Pietsch, Ines Fößl, Friederike Thomasius
Osteologie.2024; 33(02): 80. CrossRef Denosumab and the Rebound Effect: Current Aspects of Osteoporosis Therapy (Review)
N. Yu. Velts, O. V. Velts, R. N. Alyautdin
Safety and Risk of Pharmacotherapy.2024; 12(2): 190. CrossRef Denosumab Can Prevent Collapse in Patients with Early‐Stage Steroid‐Induced Osteonecrosis of the Femoral Head by Inhibiting Osteoclasts and Autophagy
Bo Liu, Feng Gao, Xiaofei Xiu, Tao Wu, Zeming Liu, Bingshi Zhang, Sikai Liu, Yongtai Han
Orthopaedic Surgery.2023; 15(1): 256. CrossRef Long-term and sequential treatment for osteoporosis
Ines Foessl, Hans P. Dimai, Barbara Obermayer-Pietsch
Nature Reviews Endocrinology.2023; 19(9): 520. CrossRef
|